InsiderTrades.com logo
Michael Albert Alrutz net worth and biography
  • Phone
  • Email
  • Website

Michael Alrutz Biography and Net Worth

Senior Vice President and General Counsel of Chimerix

Dr. Alrutz joined Chimerix in 2012 and was named Vice President, General Counsel in September 2014. From 2002 to 2011, Dr. Alrutz was counsel to Trimeris, Inc. (NASDAQ: TRMS), serving in a variety of in-house positions, most recently as General Counsel. While at Trimeris, Dr. Alrutz had primary responsibility and oversight of the company’s legal department during the development and commercialization of FUZEON®, a first-in-class viral fusion inhibitor for the treatment of HIV. Dr. Alrutz received his JD from Duke University School of Law and his PhD in molecular biology from the Tufts University Sackler School of Biomedical Sciences. He received his B.A. from the University of Pennsylvania.

What is Michael Albert Alrutz's net worth?

The estimated net worth of Michael Albert Alrutz is at least $1.82 million as of February 13th, 2025. Dr. Alrutz owns 213,596 shares of Chimerix stock worth more than $1,824,110 as of May 4th. This net worth approximation does not reflect any other investments that Dr. Alrutz may own. Additionally, Dr. Alrutz receives a salary of $571,940.00 as Senior Vice President and General Counsel at Chimerix. Learn More about Michael Albert Alrutz's net worth.

How old is Michael Albert Alrutz?

Dr. Alrutz is currently 54 years old. There are 5 older executives and no younger executives at Chimerix. The oldest executive at Chimerix is Dr. Allen S. Melemed M.B.A., M.D., Chief Medical Officer, who is 60 years old. Learn More on Michael Albert Alrutz's age.

What is Michael Albert Alrutz's salary?

As the Senior Vice President and General Counsel of Chimerix, Inc., Dr. Alrutz earns $571,940.00 per year. There are 2 executives that earn more than Dr. Alrutz. The highest earning executive at Chimerix is Mr. Michael T. Andriole M.B.A., CEO, President & Director, who commands a salary of $820,000.00 per year. Learn More on Michael Albert Alrutz's salary.

How do I contact Michael Albert Alrutz?

The corporate mailing address for Dr. Alrutz and other Chimerix executives is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. Chimerix can also be reached via phone at (919) 806-1074 and via email at ir@chimerix.com. Learn More on Michael Albert Alrutz's contact information.

Has Michael Albert Alrutz been buying or selling shares of Chimerix?

Michael Albert Alrutz has not been actively trading shares of Chimerix in the last ninety days. Most recently, Michael Albert Alrutz sold 1,600 shares of the business's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $4.52, for a transaction totalling $7,232.00. Following the completion of the sale, the senior vice president now directly owns 213,596 shares of the company's stock, valued at $965,453.92. Learn More on Michael Albert Alrutz's trading history.

Who are Chimerix's active insiders?

Chimerix's insider roster includes Michael Alrutz (Senior Vice President and General Counsel), Michael Andriole (President, CEO, and Director), Martha Demski (Director), David Jakeman (Insider), Michelle LaSpaluto (Chief Financial Officer), Allen Melemed (Chief Medical Officer), Robert Meyer (Director), and Fred Middleton (Director). Learn More on Chimerix's active insiders.

Are insiders buying or selling shares of Chimerix?

In the last twelve months, insiders at the biopharmaceutical company sold shares 9 times. They sold a total of 22,045 shares worth more than $92,241.70. The most recent insider tranaction occured on February, 13th when insider Allen S Melemed sold 3,065 shares worth more than $13,792.50. Insiders at Chimerix own 13.1% of the company. Learn More about insider trades at Chimerix.

Information on this page was last updated on 2/13/2025.

Michael Albert Alrutz Insider Trading History at Chimerix

See Full Table

Michael Albert Alrutz Buying and Selling Activity at Chimerix

This chart shows Michael Albert Alrutz's buying and selling at Chimerix by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$5k$0$5kTotal Insider BuyingTotal Insider Selling

Chimerix Company Overview

Chimerix logo
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $8.54
Low: $8.54
High: $8.54

50 Day Range

MA: $8.15
Low: $4.60
High: $8.55

2 Week Range

Now: $8.54
Low: $0.75
High: $8.55

Volume

N/A

Average Volume

2,326,581 shs

Market Capitalization

$801.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A